Analysts See $-0.95 EPS for Intra-Cellular Therapies, Inc. (ITCI)

Investors sentiment decreased to 0.94 in Q3 2018. Its down 0.30, from 1.24 in 2018Q2. It worsened, as 9 investors sold Intra-Cellular Therapies, Inc. shares while 39 reduced holdings. 11 funds opened positions while 34 raised stakes. 36.60 million shares or 0.99% less from 36.97 million shares in 2018Q2 were reported.
Bancorp Of New York Mellon reported 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Point72 Asset Mgmt L P reported 634,466 shares. Proshare Advsrs Limited Liability Company, a Maryland-based fund reported 27,791 shares. Alpine Woods Cap Ltd Limited Liability Company invested 0.09% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Moreover, Credit Suisse Ag has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Schroder Inv Gp reported 1.20M shares or 0.04% of all its holdings. Goldman Sachs Group holds 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 67,242 shares. Renaissance Tech Limited holds 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 46,400 shares. Hanseatic holds 0% or 42 shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 2,671 shares. Deutsche Savings Bank Ag holds 0% or 237,253 shares in its portfolio. Sei Investments Communication reported 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Bnp Paribas Arbitrage Sa invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Sg Americas Secs reported 44,454 shares. State Board Of Administration Of Florida Retirement Sys stated it has 20,462 shares or 0% of all its holdings.

Since November 9, 2018, it had 0 insider purchases, and 7 insider sales for $1.99 million activity. $109,630 worth of stock was sold by Davis Robert E on Friday, January 4. 24,566 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares with value of $284,383 were sold by Hineline Lawrence J.. $116,979 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares were sold by Vanover Kimberly E.. MARCUS JOEL S sold 32,000 shares worth $581,580. $604,310 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares were sold by Mates Sharon.

Analysts expect Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report $-0.95 EPS on March, 7.They anticipate $0.39 EPS change or 69.64 % from last quarter’s $-0.56 EPS. After having $-0.76 EPS previously, Intra-Cellular Therapies, Inc.’s analysts see 25.00 % EPS growth. The stock decreased 2.67% or $0.36 during the last trading session, reaching $13.12. About 358,491 shares traded. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has risen 1.66% since February 12, 2018 and is uptrending. It has outperformed by 1.66% the S&P500.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Ratings Coverage

Among 2 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intra-Cellular Therapies had 2 analyst reports since August 23, 2018 according to SRatingsIntel.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company has market cap of $718.01 million. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

More notable recent Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news were published by: Globenewswire.com which released: “Intra-Cellular Therapies Appoints Michael Olchaskey as Senior Vice President, Head of Regulatory Affairs – GlobeNewswire” on September 25, 2018, also Globenewswire.com with their article: “Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease at 2018 American Neurological Association Annual Meeting – GlobeNewswire” published on October 17, 2018, Globenewswire.com published: “Intra-Cellular Therapies Appoints Dr. Suresh Durgam as Senior Vice President, Late Stage Clinical Development and Medical Affairs – GlobeNewswire” on August 20, 2018. More interesting news about Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) were released by: Nasdaq.com and their article: “Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia – Nasdaq” published on December 11, 2018 as well as Finance.Yahoo.com‘s news article titled: “The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial – Yahoo! Finance News” with publication date: December 21, 2018.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Institutional Positions Chart